The role of APOE alleles in incident Parkinson's disease. The Norwegian ParkWest Study

Acta Neurologica Scandinavica

Volumn 122, Issue 6, 2010, Pages 438-441

  Vefring, H ^a   Haugarvoll, K ^b   Tysnes, O B ^b,c   Larsen, J P ^a,c   Kurz, M W ^a  

^a STAVANGER UNIVERSITY HOSPITAL   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF BERGEN   (Norway)

Author keywords

Apolipoprotein E; Familial; Genetics; Parkinson's disease

Indexed keywords

APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; GENOMIC DNA;

AGED; ARTICLE; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENE FUNCTION; GENOTYPE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NORWAY; ONSET AGE; PARKINSON DISEASE; POPULATION RESEARCH;

AGED; APOLIPOPROTEINS E; COMMUNITY HEALTH PLANNING; DISABILITY EVALUATION; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; INCIDENCE; MALE; MENTAL STATUS SCHEDULE; MIDDLE AGED; NORWAY; PARKINSON DISEASE;

EID: 77958519017     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2010.01362.x     Document Type: Article

References (17)

1. Alves G, Forsaa EB, Pedersen KF, Dreetz Gjerstad M, Larsen JP. Epidemiology of Parkinson's disease. J Neurol 2008;255(Suppl 5):18-32.
2. Hughes AJ, Daniel SE, Blankson S, Lees AJ. A clinicopathologic study of 100 cases of Parkinson's disease. Arch Neurol 1993;50:140-8.
3. Jellinger KA. Neuropathological aspects of Alzheimer disease, Parkinson disease and frontotemporal dementia. Neurodegener Dis 2008;5:118-21.
4. Serretti A, Olgiati P, De Ronchi D. Genetics of Alzheimer's disease. A rapidly evolving field. J Alzheimers Dis 2007;12:73-92.
5. Klein C, Schlossmacher MG. Parkinson disease, 10 years after its genetic revolution: multiple clues to a complex disorder. Neurology 2007;69:2093-104.
6. Deng H, Zhu SH, Le WD et al. Examination of the MSX1 gene in patients with Parkinson's disease. Acta Neurol Scand 2009;120:442-4.
7. Myhre R, Toft M, Kachergus J et al. Multiple alpha synuclein polymorphisms are associated with Parkinson's disease in a Norwegian population. Acta Neurol Scand 2008;118:320-7.
8. Alves G, Muller B, Herlofson K et al. Incidence of Parkinson's disease in Norway. The Norwegian ParkWest study. J Neurol Neurosurg Psychiatry 2009;80:851-7.
9. Singh PP, Singh M, Mastana SS. APOE distribution in world populations with new data from India and the UK. Ann Hum Biol 2006;33:279-308.
10. Blazquez L, Otaegui D, Saenz A et al. Apolipoprotein E epsilon4 allele in familial and sporadic Parkinson's disease. Neurosci Lett 2006;406:235-9.
11. Huang X, Chen PC, Poole C. APOE-e2 allele associated with higher prevalence of sporadic Parkinson disease. Neurology 2004;62:2198-202.
12. Williams-Gray CH, Goris A, Saiki M et al. Apolipoprotein E genotype as a risk factor for susceptibility to and dementia in Parkinson's disease. J Neurol 2009;256:493-8.
13. Aarsland D, Perry R, Brown A, Larsen JP, Ballard C. Neuropathology of dementia in Parkinson's disease: a prospective, community-based study. Ann Neurol 2005;58:773-6.
14. Wakabayashi K, Kakita A, Hayashi S et al. Apolipoprotein E epsilon4 allele and progression of cortical Lewy body pathology in Parkinson's disease. Acta Neuropathol (Berl) 1998;95:450-4.
15. Ghebremedhin E, Del Tredici K, Vuksic M et al. Relationship of apolipoprotein E and age at onset to Parkinson disease neuropathology. J Neuropathol Exp Neurol 2006;65:116-23.
16. Masliah E, Rockenstein E, Veinbergs I et al. Beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proc Natl Acad Sci USA 2001;98:12245-50.
17. Gallardo G, Schluter OM, Sudhof TC. A molecular pathway of neurodegeneration linking alpha-synuclein to ApoE and Abeta peptides. Nat Neurosci 2008;11:301-8.